Cefpodoxime (Cefpodoximum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Cephalosporins

Included in the formulation
  • Doxef
    pills inwards 
    Lupine Co., Ltd.     India
  • Sephpotek®
    pills inwards 
    Nobel Ilach Sanayi Ve Tidjaret A.Sh.     Turkey
    • АТХ:

    J.01.D.D.13   Cefpodoxime

    Pharmacodynamics:

    Semisynthetic cephalosporin antibiotic III generation.

    Has bactericidal action due to inhibition of bacterial cell wall synthesis. Violates the synthesis of the biopolymer peptidoglikana - the main component of the cell wall of bacteria. It inhibits the peptidoglycan transpeptidase, inhibits the activity of the endogenous inhibitor, which leads to activation of murein hydrolase, which cleaves peptidoglycan. Effective against fissile bacteria, in the walls of which the synthesis of peptidoglycan occurs.

    It is active against many Gram-positive, Gram-negative, aerobic and anaerobic microorganisms.

    Insensitive to the drug Corynebacterium groups J and K, Staph., resistant to methicillin, Str. group D, Acinetobacter baumannii, Listeria monocytogenes, Pseudomonas, Bacteroides and Cl. difficile.

    Resistant to the action of β-lactamases.

    Pharmacokinetics:

    After oral administration, an empty stomach is absorbed in the gastrointestinal tract up to 50%. The maximum concentration in the blood plasma is achieved in 2-3 hours. The connection with plasma proteins is 20-30%.

    Not exposed to metabolism. Does not penetrate the blood-brain barrier.

    The half-life is 2.1-2.8 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of infectious and inflammatory diseases caused by microorganisms sensitive to cephodoxim: upper and lower respiratory tracts - tonsillitis, pharyngitis, acute sinusitis, pneumonia, acute bronchitis, exacerbation of chronic bronchitis (in people who abuse alcohol, smokers and people over 65) .

    ICD-10

    X.J00-J06.J00   Acute nasopharyngitis (runny nose)

    X.J30-J39.J31.1   Chronic nasopharyngitis

    X.J30-J39.J31   Chronic rhinitis, nasopharyngitis and pharyngitis

    X.J00-J06.J01   Acute Sinusitis

    X.J30-J39.J32   Chronic Sinusitis

    X.J30-J39.J31.2   Chronic pharyngitis

    X.J00-J06.J02   Acute pharyngitis

    X.J00-J06.J03   Acute tonsillitis

    X.J30-J39.J35.0   Chronic tonsillitis

    X.J00-J06.J04   Acute laryngitis and tracheitis

    X.J10-J18.J15   Bacterial pneumonia, not elsewhere classified

    X.J20-J22.J20   Acute bronchitis

    X.J40-J47.J42   Chronic bronchitis, unspecified

    Contraindications:

    Individual intolerance of β-lactam antibiotics: penicillins and cephalosporins, children under 12 years.

    Carefully:

    Imbalance of electrolytes or fluid, a history of bronchial asthma, severe liver damage, malabsorption syndrome.

    Pregnancy and lactation:

    Recommendations for FDA - Category B.It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Inside at meal time to 200-400 mg 2 times a day.

    The highest daily dose: 800 mg.

    The highest single dose: 400 mg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness.

    Hemopoietic system: leukopenia, thrombocytopenia, hemolytic anemia, eosinophilia, hypoprothrombinemia.

    Digestive system: nausea, vomiting, diarrhea, cholestatic jaundice, pseudomembranous colitis, increased activity of hepatic transaminases, hepatitis.

    Dermatological reactions: hyperhidrosis, rash, itching, candidiasis.

    Urinary system: interstitial nephritis.

    Allergic reactions.

    Overdose:

    Increased side effects.

    Treatment is symptomatic.

    Interaction:

    When used simultaneously with aminoglycosides, butadione, polymyxins, the risk of nephrotoxicity increases.

    Increase the effect of aminoglycosides, metronidazole, polymyxins, rifampicin, weaken - levomitsetin, tetracyclines.

    Reduces the bioavailability of histamine H blockers2-receptors (including ranitidine) and antacid preparations (aluminum hydroxide, sodium bicarbonate).

    Kolestyramin reduces the absorption of cefpodoxime.

    Special instructions:

    During treatment, a false positive Coombs reaction and a false positive urine reaction to glucose are possible.

    Instructions
    Up